Linkage analyses of bipolar families have confirmed that there is a susceptibility locus near the telomere on chromosome 21q. To fine map this locus we carried out tests of allelic association using 30 genetic markers near the telomere at 21q22.3 in 600 bipolar research subjects and 450 ancestrally matched supernormal control subjects. We found significant allelic association with the microsatellite markers D21S171 (P ¼ 0.016) and two closely linked single-nucleotide polymorphisms, rs1556314 (P ¼ 0.008) and rs1785467 (P ¼ 0.025). A test of association with a three locus haplotype across the susceptibility region was significant with a permutation test of P ¼ 0.011. A two SNP haplotype was also significantly associated with bipolar disorder (P ¼ 0.01). Only two brain expressed genes, TRPM2 and C21ORF29 (TSPEAR), are present in the associated region. TRPM2 encodes a calcium channel receptor and TSPEAR encodes a peptide with repeats associated with epilepsy in the mouse. DNA from subjects who had inherited the associated marker alleles was sequenced. A base pair change (rs1556314) in exon 11 of TRPM2, which caused a change from an aspartic acid to a glutamic acid at peptide position 543 was found. This SNP showed the strongest association with bipolar disorder (P ¼ 0.008). Deletion of exon 11 of TRPM2 is known to cause dysregulation of cellular calcium homeostasis in response to oxidative stress. A second nonconservative change from arginine to cysteine at position 755 in TRPM2 (ss48297761) was also detected. A third nonconservative change from histidine to glutamic acid was found in exon 8 of TSPEAR. These changes need further investigation to establish any aetiological role in bipolar disorder.
Introduction
Bipolar affective disorder (BPAD [MIM 125480]) has a lifetime risk of 0.3-1.5%. The disorder is characterised by episodes of mania and depression. Family, twin, and adoption studies have demonstrated that genetic factors contribute strongly to the aetiology of bipolar and genetically related unipolar affective disorders. [1] [2] [3] Specific disease alleles or aetiological DNA changes have yet to be identified. Linkage analyses have shown extensive locus heterogeneity for bipolar disorders. Linkage on chromosome 21q to bipolar and genetically related unipolar affective disorder was first reported in 1994 4 and this has been confirmed with multiple lods between 2.00 and 3.00 as shown in Table 1 . [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The linkage studies support linkage to a bipolar susceptibility locus at the telomere (21q22.3) and also at a slightly more proximal region. 8, 16 Our own parametric linkage analysis 10 favoured the more telomeric localisation for a chromosome 21q22.3 susceptibility locus, which was the region we targeted for fine mapping.
Materials and methods
The research has received UK NHS Multicentre Research Ethics Committee (MREC) approval from the London Metropolitan MREC. In total, 600 subjects with bipolar disorder and 450 normal controls gave informed and signed consent. The cases were recruited from London NHS psychiatric services and from volunteers who were members of a support organisation for sufferers of BPADs living in South East England. The control subjects were recruited from London branches of the National Blood Service, from local NHS family doctor clinics and from university student volunteers. In order to reduce the likelihood of population stratification between the case and control samples, bipolar case and control recruitment was strictly based on an ancestry questionnaire. For selection into the study the ancestry of both parents and all four grandparents must have been Irish, Welsh, Scottish or English. Subjects were also included if one of the four grandparents was of European Union (EU) ancestry before the 2004 EU enlargement. In order to detect population stratification or genetic heterogeneity between the case and control samples and to validate the ancestry questionnaire the first 300 of the bipolar and 300 of the controls cases were genotyped with 26 microsatellite markers at loci not thought to be associated with affective disorders. All case and control subjects were interviewed using the Lifetime Version of the Schizophrenia and Affective Disorders Schedule (SADS-L). 17 This information was supplemented by material from case-notes. Diagnoses were assigned blind to genotype information using the Research Diagnostic Criteria (RDC). 18 A second psychiatrist confirmed the diagnoses. DNA was extracted from whole frozen venous blood using a cell lysis, proteinase K, phenol/ chloroform method. 19 Genotyping was carried using genomic DNA amplified by polymerase chain reaction (PCR) under specific temperature and cycling conditions for each pair of oligonucleotide primers. Oligonucleotide sequence information for the following markers was obtained from the GDB: D21S266, D21S1260, D21S212, White-PolyT, D21S1411, PKNOX1-CA, TMEM1_IN/DEL, PFKL-CA, D21S171, D21S1903, ITGB2-AciI, D21S1897 and S100B-HaeIII. Sequence information for the following SNPs was obtained from dbSNP: rs1556314, rs1785437, rs1618355, rs933151, rs1785467, rs458178 and rs233283. In total, 10 additional polymorphisms were typed in this study: 22A5.GT124, 218C10.CA44, C21ORF2, 20 AGAT10, ATTT11, 314n7CT18, 314n7CA28, 314n7CA23, Col6a1-VNTR and PCNT2-AluI RFLP. Oligonucleotide sequences for these markers are shown in Table 2 . For microsatellites one of the primers was synthesised with an extra length (tail) of M13 DNA sequence for hybridisation with a universal infrared dye labelled M13 sequence oligonucleotide. Microsatellite allele sizes were resolved by polyacrylamide gel electrophoresis on LiCor 4200L sequencers. Fluorescent images were analysed using RFLPScan (Scanalytics, VA, USA). The C21ORF2 and TMEM1 insertion/deletion polymorphisms were genotyped using PCR with a 32 P labelled oligonucleotide primer followed by PAGE and autoradiography. Col6A1 VNTR alleles were genotyped by PCR and agarose gel electrophoresis. SNPs were typed by PCR/RFLP/agarose gels, Pyrosequencing, Taqman or with Amplifluor methods. Restriction enzymes used for the PCR/RFLP assays are included as part of the marker name. SNPs rs1556314 and rs1785437 were typed using Pyrosequencing, according to the manufacturer's instructions (Pyrosequencing). SNP rs1618355 and rs458178 were typed using Taqman MGB probes, according to the manufacturer's instructions (Applied Biosystems). SNPs rs933151, rs1785467 and rs233283 were typed using Amplifluor reagents, according to the manufacturer's instructions (Serologicals).
Genotypes were read by two independent assessors blind to each other's genotypes and blind to diagnosis. Genotypes that could not be agreed upon were repeated. Tests of allelic association that incorporated a Monte Carlo empirical test of significance, which does not need further correction for multiple alleles were carried out using CLUMP. 21 Maximum likelihood estimates of haplotype frequencies were computed with GENECOUNTING 22 and empirical tests of significance of haplotypic association, which do not need further correction for multiple haplotypes were computed with permutation tests. 23 The genes TSPEAR and TRPM2 were screened for polymorphisms and mutations in bipolar subjects selected for having inherited polymorphisms associated with or linked to the chromosome 21q2.3 bipolar locus and in four control subjects. M13 tailed primers were designed to sequence all the exons and 100 bases into each intron. Sequencing was preformed using an M13 dye labelled primer as described above. In total, 28 bipolar subjects were chosen for sequencing. These included 16 affected members from seven English bipolar families and In
seven NIMH bipolar families that had produced LOD scores 41 on 21q. A further 12 bipolar patients were selected from the association sample based on the fact that they carried alleles associated at the D21S171 and AGAT10 loci. In total, 36 samples chosen from the control sample without regard to their genotypes at the chromosome 21 locus were also sequenced to verify whether detected nucleotide changes were likely to be pathogenic or simply common polymorphisms. Where the nucleotide change was not observed in the first 36 samples additional control samples were also sequenced.
Results
The alleles and genotypes of 26 microsatellite markers at loci not thought to be associated with affective disorders did not show any significant differences between the case and control samples in the initial samples of 300 cases and 300 controls. In total, 18 microsatellite or multiallelic VNTRs and 12 bi-allelic polymorphisms in the 21q22 linkage region were analysed in the case-control association sample (Table 3) . Two microsatellites D21S171 and D21S1260 provided evidence for association with bipolar disorder. D21S171 was significant with empirical P-values of 0.016 and 0.034 with the T3 and T4 tests of CLUMP. 21 D21S1260 also showed evidence for association with the CLUMP T3 statistic 21 w 2 ¼ 8.128 (P ¼ 0.031). In the region surrounding D21S171, the microsatellite AGAT10 did not show significant allelic association with the empirical test of significance implemented in CLUMP. However, when each allele was compared with the sum of the remaining alleles in a 2 Â 2 contingency table, an uncorrected P-value of 0.026 was obtained. Seven SNPs were typed within the 90 kb AGAT10-D21S171 region. Two of these showed allelic association with (Figure 1) .
The results of pair wise marker to marker linkage disequilibrium (LD) analyses performed on data from the bipolar subjects and controls are shown in Figure  2 . The data show that for the majority of the microsatellite markers only limited LD was observed.
However, in the region between AGAT10 and D21S171 relatively high levels of LD were observed; therefore, data for markers in this area were used for haplotype analysis with GENECOUNTING. 22 Using the asymptotic distribution, the test for haplotype association for the two associated SNPs rs1556314 and rs1785467 was significant at P ¼ 0.009 and for the two associated SNPs and the associated microsatellite D21S171 of P ¼ 0.007. The empirical P-values for A bipolar disorder susceptibility locus on 21q22.3 A McQuillin et al these haplotype associations using permutation tests were P ¼ 0.01 and 0.011, respectively. Haplotype BP1 was a major contributor to the difference in estimated haplotype frequencies although other haplotypes also made a contribution as shown in Table 4 . Haplotype BP1 is made up of adjacent SNP alleles T-A. The estimated frequencies of this haplotype in bipolar subjects and control chromosomes are 81 and 74%, respectively ( Table 4 ). The estimated frequencies of the related haplotype BP6 made up of the adjacent SNP alleles above and D21S171 allele 227 (T-A-227) in bipolar subjects and control chromosomes are 43 and 34%, respectively ( Table 4 ). The results of the tests of allelic and haplotypic association with bipolar disorder indicate that there is LD between marker alleles and potential aetiological base pair changes within or near to the TRPM2 and/or TSPEAR genes.
No other candidate genes are in the region. The sequencing of the two genes detected SNPs rs1556314, rs9974831, rs1785437 and five novel polymorphisms (Table 5) . SNPs rs1556314 and rs1785437 were subsequently genotyped in the case-control sample. The minor allele frequency of SNP rs1556314 was significantly increased in controls (23%) compared to bipolar cases (18%). rs1556314 is in exon 11 of TRPM2 and causes an amino-acid change from aspartic acid to glutamic acid at position 543. SNP rs1785437 allele frequencies were similar in the bipolar cases (25%) and controls (23%). Another detected polymorphism (ss48297761) is located in exon 15 of TRPM2 and was predicted to alter amino acid at position 755 from arginine to cysteine. This amino acid is located in part of one of Two marker haplotypes (overall empirical significance
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The allelic composition and frequencies of selected haplotypes generated from GENECOUNTING analysis of data from SNPs rs1556314 and rs1785467. GENECOUNTING analysis was also performed on data from SNPs rs1556314, rs1785467 and D21S171 (see Results section). Analysis of the amino acid change with transmembrane structure prediction programmes TMHMM and TMpred did not predict significant alterations in TRPM2 transmembrane structures. Further studies of this SNP are needed in a larger sample. An SNP in exon 8 of TSPEAR (ss48297763) was predicted to alter amino acid 408 from histidine to glutamine. ss48297763 was observed in three of 28 bipolar patients and in three of 48 controls that were sequenced. An additional coding region SNP that was not predicted to alter an amino acid was also detected in exon 6 of the TRPM2 gene (ss48297759). This SNP was observed in one of 28 bipolar patients and not in any of 36 controls. From an evolutionary standpoint we note that for the SNP ss48297759, alignment of human, chimp, rat and mouse exon 6 TRPM2 sequences on the UCSC genome browser shows conservation of the major allele (G) in human, chimp and rat, but the rare SNP allele (A) is observed in the mouse. Two remaining intronic SNPs were also detected, in intron 8 of TRPM2 a substitution 78 nucleotides before exon 9 (ss48297760) was detected in one of four controls examined and not in any of 28 bipolar patients. In intron 7 of TSPEAR a substitution was detected 26 nucleotides before exon 8 (ss48297762) in one of 28 bipolar patients but in none of 48 controls. None of the SNPs detected here obviously represent pathogenic mutations.
Discussion
This study has found evidence for the fine mapping of a BPAD to a 200 kb telomeric region of chromosome 21, which is 44.7 megabases from the telomere of the short arm. The region showing association is compatible with all the linkage studies implicating bipolar disorder to the telomere of 21q as shown in Table 1 with the possible exception of the study on the NIMH Clinical Neurogenetics Branch bipolar family sample, which also implicated a region which was 9-15 cM proximal to the telomeric region implicated in the majority of studies. 8 This is consistent with a possibility of there being two bipolar susceptibility loci on 21q but with the more telomeric locus having received better confirmation.
Although case-control analysis, as opposed to family-based association analysis, is theoretically prone to produce false positive results due to population stratification this risk has probably been exaggerated. The careful selection of cases and controls with the ancestry questionnaire and the validation of this procedure with tests of heterogeneity makes it unlikely that population stratification is the explanation for the positive results presented here. Although our tests do not require correction for multiple alleles or multiple haplotypes, the overall statistical significance of the results obtained is difficult to judge because multiple markers have been tested and the CLUMP program outputs four different test statistics. Results from different markers are likely to be correlated to some extent because of LD and the results from CLUMP are also correlated, meaning that a simple Bonferroni correction would be conservative. Bearing in mind that the region we have investigated was implicated by prior linkage studies we consider that our results do provide support for the presence of a susceptibility locus in this region, but it would certainly be helpful to obtain results from confirmatory studies in other samples.
Two genes bordering this region, the ATP-binding cassette (ABC) transporter G1 gene (ABCG1, synonyms: ABC8, human white gene) and the synaptojanin 1 gene (SYNJ1), have been tested for allelic association with bipolar disorder and also sequenced to find mutations in bipolar patients. 24, 25 Neither gene was associated with bipolar disorder, and no mutations were detected. An allele of a poly T repeat polymorphism in the 3 0 UTR of the ABCG1 genes has shown association with mood and panic disorders. 26 However, no significant association of this polymorphism with bipolar disorder was detected by Kirov et al., 24 or by ourselves. In our analyses 'risk' haplotypes derived from markers showing high levels of marker to marker LD have been identified, but we have not yet been able to pinpoint any obvious pathogenic base pair changes. The coding region and the first 500 base pairs of the promoter of both TRPM2 and TSPEAR did not show any potential aetiological base pair changes. The most promising of the two genes in the 21q22 associated region is the transient receptor potential gene melastatin 2 (TRPM2), which is a member of a family of calcium channel genes involved in calcium homeostasis, which is highly expressed in the brain.
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TRPM2 may also be implicated in the mechanism of lithium action by virtue of the coregulation of calcium release from internal stores and the production of inositol 1,4,5 triphosphate. 27 In another study, that became known to us after we had detected putative allelic association at 21q22.3, it was found that TRPM2 mRNA transcripts in B cell lymphoblastoid cell lines were downregulated in a subgroup of bipolar subjects with higher basal calcium levels. 28 Thus, expression of TRPM2 may be a trait involved in altered calcium homeostasis in some bipolar patients. 28 A number of differentially spliced isoforms of TRPM2 have been identified and some of these truncated peptides may have a role in regulating the function of the full-length isoform. 29 The expression of some or possibly all of these isoforms appears to be tissue specific and of note is the discovery of an N-terminal truncated TRPM2 that has only been detected in the striatum. 30 Another TRPM2 isoform has been isolated that has the residues encoded by part of exon 11 and all of exon 27 deleted. In contrast to full-length TRPM2 and exon 27 deleted TRPM2, the exon 11 TRPM2 deletion did not respond to H 2 O 2 stimulation. 31 SNP rs1556314, which showed the most significant association with bipolar disorder in this study, causes a conservative amino acid change in the exon 11 deleted region, but there is no evidence that this change has any role in either the dysregulation of cellular calcium homeostasis in response to oxidative stress or in bipolar disorder susceptibility. The other candidate gene, TSPEAR, is located distally to TRPM2 and contains repeat elements which are homologous to mouse audiogenic epilepsy associated DNA repeats (EAR). 32 Mutations in homologues to this gene cause nonion channel epilepsy in both mouse and human epilepsy. The EAR domain consists of a 44 amino-acid residue motif repeated seven times. The EAR is a member of the class of protein interaction domains with a seven-bladed beta-propeller fold. In several genes, the EAR is part of a ligandbinding ectodomain and is predicted to be part of secreted proteins consisting of an N-terminal leucinerich repeat region and a C-terminal EAR region. 32 The human genome may have been sequenced but it has not been fully characterised and annotated. It is possible that other expressed sequences and also intronic or locus control region changes, which we have not sequenced, may be causing the genetic susceptibility to bipolar and unipolar affective disorders.
The positive linkage results at 21q22.3 that we and others have detected in multiply affected families are further supported by this finding of association. It is noteworthy that this sample consists of unrelated bipolar subjects who were not selected for having a positive family history and this suggests that bipolar disorder in general psychiatric hospital patients is due in part to the 21q22.3 susceptibility locus detected in multiply affected extended pedigrees. Linkage to 21q22.3 was found in families with a 50:50 ratio of bipolar and unipolar affective disorders; therefore, the susceptibility locus we have mapped may also predispose to a proportion of unipolar affective disorder cases. For this reason, attempts at replication of the allelic association should be carried out in other samples of both bipolar and unipolar disorder.
